Skip to main content
. 2011 Jul 29;118(17):4541–4546. doi: 10.1182/blood-2011-04-348110

Table 2.

CCyR at 3, 6, and 12 months by therapy

3 months
6 months
12 months
Evaluable CCyR % P Evaluable CCyR % P Evaluable CCyR % P
IM 400 mg 70 27 39 70 37 53 68 45 66
IM 800 mg 199 125 63 < .001 194 164 85 < .001 187 169 90 < .001
Second TKI 141 114 81 131 125 95 118 116 98

Evaluable indicates patients who received therapy and were evaluable for cytogenetic response at each time point; and IM, imatinib.